<DOC>
	<DOC>NCT00414622</DOC>
	<brief_summary>A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer’s Disease</brief_summary>
	<brief_title>GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer’s Disease</brief_title>
	<detailed_description>A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer’s Disease</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>3-(2,4-dimethoxybenzylidene)anabaseine</mesh_term>
	<criteria>probable Alzheimer others</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Alzheimer</keyword>
	<keyword>Probable Alzheimer disease</keyword>
</DOC>